Stockreport

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing LONDON--(BUSINESS WIRE)--Silence Therape [Read more]